The role of topical therapy for patients with extensive psoriasis

Cutis

Volumn 79, Issue 1 SUPPL. 2, 2007, Pages 18-31

  Feldman, Steven R ^a   Gelfand, Joel M ^b   Gold, Linda Stein ^c   Jones, Sherri D ^d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOLOGICAL THERAPY; HUMAN; PSORIASIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; BIOLOGICAL THERAPY; HUMANS; PSORIASIS;

EID: 33846880035     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152:861-867.
2. Louden BA, Pearce DJ, Lang W, et al. A simplified psoriasis area severity index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J. 2004;10:7.
3. National Psoriasis Foundation. National Psoriasis Foundation benchmark survey on psoriasis and psoriatic arthritis, summary of top-line results. Available at: http: //www.psoriasis.org/files/pdfs/press/2001benchmark survey.pdf. Accessed August 4, 2005.
4. National Psoriasis Foundation. About psoriasis statistics. Available at: http://www.psoriasis.org/about/stats. Accessed August 3, 2005.
5. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-139.
6. Gelfand JM, Wang X, Liu Q, et al. Epidemiology and treatment patterns of psoriasis in the General Practice Research Database (GPRD). Pharmacoepidemiology and Drug Safety. 2005;14:S23-S24.
7. Yosipovitch G, Goon A, Chan YH, et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000;143:969-973.
8. Amevive [package insert]. Cambridge, Mass: Biogen Idee, Inc; 2005.
9. Raptiva [package insert]. South San Francisco, Calif: Genentech, Inc; 2005.
10. Enbrel [package insert]. Thousand Oaks, Calif: Amgen, Inc; 2004.
11. Remicade [package insert]. Malvern, Pa: Centocor, Inc; 2005.
12. Humira [package insert]. North Chicago, Ill: Abbott Laboratories; 2005.
13. Lebwohl M, Christopher E, Langley R, et al, Alefacept Clinical Study Group. Placebo-controlled phase III trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-727.
14. Gordon KB, Papp KA, Hamilton TK, Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290:3073-3080.
15. Lebwohl M, Tyring SK, Hamilton TK, et al, Efalizumab Study Group. A novel targeted T-cell moduktor, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-2013.
16. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-1632.
17. Leonardi C, Powers JL, Matheson RT, et al, Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engi J Med. 2003;349:2014-2022.
18. Papp KA, Tyring S, Lahfa M, et al, Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312.
19. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial, Lancet. 2001;357:1842-1847.
20. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534-542.
21. Ortonne JP. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003;17:12-16.
22. Gottlieb AB, Chaudhari U, Mulcahy LD, et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003;48:829-835.
23. Leonardi CL, Papp KA, Gordon KB, et al, Efalizumab Study Group. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005;52:425-433.
24. Mensing H, Korsukewitz G, Yawalkar S. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. J Am Acad Dermatol. 1991;25:1149-1152.
25. Blum G, Yawalkar S, A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991;25:1153-1156.
26. Goldberg B, Hartdegen R, Presbury D, et al. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991;25:1145-1148.
27. Shupack JL, Jondreau L, Kenny C, et al. Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis. Dermatology. 1993;186:129-132.
28. Katz HI, Gross E, Buxman M, et al. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis. J Am Acad Dermatol. 1991;25:1175-1178.
29. Bernhard J, Whitmore C, Guzzo C, et al. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehiclecontrolled studies. J Am Acad Dermatol. 1991;25:1170-1174.
30. Ellis CN, Katz HI, Rex IH Jr, et al. A controlled clinical trial of a new formulation of betamethasone dipropionate cream in once-daily treatment of psoriasis. Clin Ther. 1989;11:768-774.
31. Katz HI, Hien NT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris - clinical efficacy and adrenal function. J Am Acad Dermatol. 1987; 16: 804-811.
32. Decroix J, Pres H, Tsankov N, et al. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. Cutis. 2004;74:201-206.
33. Lebwohl M, Sherer D, Washenik K, et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol. 2002;41:269-274.
34. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7:185-192.
35. Callen J. Comparison of safety and efficacy of fluticasone propionate cream, 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of moderate-to-severe psoriasis. Cutis. 1996;57(suppl 2):45-50.
36. Nürnberger FG. A comparison of fluticasone propionate ointment, 0.005%, and hydrocortisone-17-butyrate ointment, 0.1%, in the treatment of psoriasis. Cutis. 1996;57(suppl 2):39-44.
37. Roberts DT. Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis. Cutis. 1996;57(suppl 2):27-31.
38. Pinheiro N. Comparative effects of calcipotriol ointment (50 micrograms/g) and 5% coal tar/2% allantoin/0.5% hydrocortisone cream in treating plaque psoriasis. Br J Clin Pract. 1997;51:16-19.
39. Weinstein GD, Koo JY, Krueger GG, et al, Tazarotene Cream Clinical Study Group. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48:760-767.
40. Hughes J, Rustin M. Corticosteroids. Clin Dermatol 1997;15:715-721.
41. Mikhail M, Scheinfeld N. Evidence-based review of topical treatments for psoriasis. Adv Stud Med. 2004;4:420-429.
42. Highton A, Quell J. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. J Am Acad Dermatol. 1995;32:67-72.
43. Molin L. Topical calcipotriol combined with phototherapy for psoriasis, the results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. Dermatology. 1999;198:375-381.
44. Krueger GG, Drake LA, Elias PM, et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 1998;134:57-60.
45. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92.
46. Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;38:705-711.
47. Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet. 1991;337:193-196.
48. Bruce S, Epinette WW, Funicella T, et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994;31:755-759.
49. Molin L, Cutler TP, Helander I, et al. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis, a randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. Br J Dermatol 1997; 136:89-93.
50. Cunliffe WJ, Berth-Jones J, Claudy A, et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol. 1992;26:736-743.
51. Koo J, Behnam SE, Behnam SM. The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis. Expert Opin Pharmacother. 2003;4:2347-2354.
52. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82:131-135.
53. Guenther L, Cambazard F, van de Kerkhof PC, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehiclecontrolled clinical trial. Br J Dermatol. 2002;147:316-323.
54. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205:389-393.
55. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54.
56. Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004;150:1167-1173.
57. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/ Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006;154:1155-1160.
58. van de Kerkhof PC. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol. 2004:151:663-668.
59. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriene in psoriasis vulgaris. Acta Derm Venereol. 2002;82:131-135.
60. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140:408-414.
61. Data on file. Rockaway, NJ: Warner Chilcott (US), Inc; 2003.
62. Stern RS. Psoriasis. Lancet. 1997;350:349-353.
63. Kragballe K, Stein Gold L, Ganslandt C. Long-term usage of a calcipotriol/betamethasone 2-compound ointment in patients with severe psoriasis: a 52-week study. Presented at: European Academy of Dermatology and Venerology: 4th European Academy of Dermatology and Venerology Spring Symposium; February 9-12, 2006; Saariselkä, Lapland, Finland.
64. Craze M, Young M. Integrating biologic therapies into a dermatology practice: practical and economic considerations. J Am Acad Dermatol. 2003;49(suppl 2):S139-S142.
65. Anstey AV, Kragballe K. A retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol. 2006;45:970-975.